Study 2 of 6Pramlintide literatureNature metabolismTop journal2026
The story of amylin: from physiology to therapy.
Not reported in abstract.
Where it sits
this study against the rest of the pramlintide corpus4
Preclinical · this one
2
Observational
0
Open-label
0
Randomised
0
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Pramlintide corpus
DAmylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?Lancet (London, England) · 2026 · Not reported in abstract.—BImmune pathways and prenatal/perinatal environmental exposures contribute to epigenetic gestational age prediction and acceleration.Epigenetics · 2026 · n=391 · R² = 0.88 for multi-CpG site model predictive accuracy.HumanCThe cyclin dependent kinase (CDK)7 inhibitor BS-181 inhibits pathogenic Cryptococcus species, causing G<sub>2</sub>/M arrest and a splicing defect.Virulence · 2026 · 2-4-fold reduction in the amphotericin B MIC with BS-181.AnimalDEffect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.JAMA · 2022—DAmylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?Lancet (London, England) · 2026—